Celcuity (NASDAQ:CELC) Sets New 1-Year High After Analyst Upgrade

Celcuity, Inc. (NASDAQ:CELC)’s stock price hit a new 52-week high during trading on Monday after Guggenheim raised their price target on the stock from $135.00 to $165.00. Guggenheim currently has a buy rating on the stock. Celcuity traded as high as $142.50 and last traded at $140.0780, with a volume of 49816 shares trading hands. The stock had previously closed at $125.65.

CELC has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Monday, April 20th. Citizens Jmp started coverage on shares of Celcuity in a report on Monday, April 27th. They issued a “market outperform” rating and a $150.00 price target on the stock. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Wolfe Research reissued an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Finally, Stifel Nicolaus set a $150.00 target price on Celcuity in a research report on Monday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $125.40.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This represents a 30.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.33% of the company’s stock.

Institutional Trading of Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new position in Celcuity during the first quarter valued at approximately $1,553,000. Abel Hall LLC bought a new stake in shares of Celcuity in the 1st quarter worth approximately $236,000. Pictet Asset Management Holding SA purchased a new stake in shares of Celcuity in the 1st quarter valued at $358,000. Hsbc Holdings PLC purchased a new stake in shares of Celcuity in the 4th quarter valued at $1,058,000. Finally, Seven Fleet Capital Management LP bought a new position in shares of Celcuity during the 4th quarter valued at $783,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

The company has a market cap of $6.90 billion, a PE ratio of -37.88 and a beta of 0.09. The business’s 50-day moving average is $114.53 and its 200 day moving average is $102.64. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.09. On average, equities research analysts predict that Celcuity, Inc. will post -3.97 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.